Autonomous Sandoz Set To Be Tighter And Leaner
With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.
You may also be interested in...
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
Sandoz CEO Richard Saynor has told Generics Bulletin that the firm’s focus and strategy remain “unchanged” in the wake of last week’s announcement by parent company Novartis that it was exploring its options for the generics and biosimilars business.
Novartis gave further color during its Q3 earnings call on its plans to conduct a strategic review for its Sandoz business. The Street also had its say, following years of calls by investors for Novartis to weigh Sandoz’ future as part of the group.